Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21

Abstract

Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas. By positional cloning of amplified genes by yeast artificial chromosome-mediated cDNA capture using magnetic beads, we have identified three candidate genes (COAS1, -2 and -3) in the amplified region in sarcomas. COAS1 and -2 showed higher amplification levels than COAS3. Most notably, amplification was very common in osteosarcomas, where in particular COAS2 was highly expressed. COAS1 has multiple repeats and shows no homology to previously described genes, whereas COAS2 is a novel member of the cyclosporin-binding peptidyl-prolyl isomerase family, very similar to cyclophilin A. COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistant tumours. Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common. All three genes were found to be amplified and over-expressed also in breast carcinomas. The complex nature of the 1q21-23 amplicons and close proximity of the genes make unequivocal determination of the gene responsible difficult. Quite likely, the different genes may give selective advantages to different subsets of tumours.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, van Dekken H . 2000 Lab. Invest. 80: 931–942

  • Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman D . 1997 Nucleic Acids Res. 25: 3389–3402

  • Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, Amann G, Kovar H, Horcher E, De Bernardi B, Michon J, Gadner H . 2001 Med. Ped. Oncol. 36: 1–4

  • Arevalo-Rodriguez M, Cardenas ME, Wu X, Hanes SD, Heitman J . 2000 EMBO J. 19: 3739–3749

  • Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O . 1996 Genes Chrom. Cancer 17: 254–259

  • Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Gray JW . 1998 Proc. Natl. Acad. Sci. USA 95: 8703–8708

  • Corton JC, Moreno ES, Merritt A, Bocos C, Cattley RC . 1998 Cancer Lett. 134: 61–71

  • Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O . 1993 Cell Growth Differ. 4: 1065–1070

  • Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A . 1995a Genes Chrom. Cancer 14: 15–21

  • Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, van Kessel AG . 1995b Genes Chrom. Cancer 14: 8–14

  • Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O . 1998 Br. J. Cancer 78: 495–503

  • Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O . 2001 Cancer Genet. Cytogenet. 125: 100–111

  • Fukuda K, Tanigawa Y, Fujii G, Yasugi S, Hirohashi S . 1998 Development 125: 3535–3542

  • Groet J, Ives JH, South AP, Baptista PR, Jones TA, Yaspo ML, Lehrach H, Potier MC, Van Broeckhoven C, Nizetic D . 1998 Genome Res. 8: 385–398

  • Gronwald J, Storkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, Lubinski J, Cremer T . 1997 Cancer Res. 57: 481–487

  • Guan XY, Fang Y, Sham JS, Kwong DL, Zhang Y, Liang Q, Li H, Zhou H, Trent JM . 2000 Genes Chrom. Cancer 29: 110–116

  • Haendler B, Hofer-Warbinek R, Hofer E . 1987 EMBO J. 6: 947–950

  • Hardas BD, Zhang J, Trent JM, Elder JT . 1994 Genomics 21: 359–363

  • Harding MW, Galat A, Uehling DE, Schreiber SL . 1989 Nature 341: 758–760

  • Hemenway CS, Heitman J . 1996 J. Biol. Chem. 271: 18527–18534

  • Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD, Berk BC . 2000 Circ. Res. 27: 789–796

  • Kiechle M, Hinrichs M, Jacobsen A, Luttges J, Pfisterer J, Kommoss F, Arnold N . 2000 Am. J. Pathol. 156: 1827–1833

  • Kim JO, Nau MM, Allikian KA, Makela TP, Alitalo K, Johnson BE, Kelley MJ . 1998 Oncogene 17: 1019–1026

  • Koletsky AJ, Harding MW, Handschumacher RE . 1986 J. Immunol. 137: 1054–1059

  • Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, Ishii K, Kita T, Kikuchi Y, Nagata I, Miwa M, Uchida K . 1999 Clin. Cancer Res. 5: 2526–2531

  • Larramendy ML, Lushnikova T, Bjorkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S . 2000 Cancer Genet. Cytogenet. 119: 132–138

  • Lioumi M, Olavesen MG, Nizetic D, Ragoussis J . 1998 Genomics 49: 200–208

  • Liu J, Chen CM, Walsh CT . 1991 Biochemistry 30: 2306–2310

  • Lovett M, Kere J, Hinton LM . 1991 Proc. Natl. Acad. Sci. USA 88: 9628–9632

  • Lu KP, Hanes SD, Hunter T . 1996 Nature 380: 544–547

  • Lu KP . 2000 Prog. Cell Cycle Res. 4: 83–96

  • Mairal A, Pinglier E, Gilbert E, Peter M, Validire P, Desjardins L, Doz F, Aurias A, Couturier J . 2000 Genes Chrom. Cancer 28: 370–379

  • Malamou-Mitsi VD, Syrrou M, Georgiou I, Pagoulatos G, Agnantis NJ . 1999 J. Exp. Clin. Cancer Res. 18: 357–361

  • Matthews CP, Shera KA, McDougall JK . 2000 Proc. Soc. Exp. Biol. Med. 223: 316–321

  • Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O . 2001 Genes Chrom. Cancer 31: 264–273

  • Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A . 1996 J. Invest. Dermatol. 106: 989–992

  • Nizetic D, Monard S, Young B, Cotter F, Zehetner G, Lehrach H . 1994 Mamm. Genome 5: 801–802

  • Ozaki K, Fujiwara T, Kawai A, Shimizu F, Takami S, Okuno S, Takeda S, Shimada Y, Nagata M, Watanabe T, Takaichi A, Takahashi E, Nakamura Y, Shin S . 1996 Cytogenet. Cell Genet. 72: 242–245

  • Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C . 1999 Genes Chrom. Cancer 24: 30–41

  • Rahfeld JU, Rucknagel KP, Schelbert B, Ludwig B, Hacker J, Mann K, Fischer G . 1994 FEBS Lett. 352: 180–184

  • Rey O, Baluda MA, Park NH . 1999 Oncogene 18: 827–831

  • Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH . 1989 Nature 341: 755–757

  • Spitzfaden C, Weber HP, Braun W, Kallen J, Wider G, Widmer H, Walkinshaw MD, Wuthrich K . 1992 FEBS Lett. 300: 291–300

  • Szymanska J, Virolainen M, Tarkkanen M, Wiklund T, Asko-Seljavaara S, Tukiainen E, Elomaa I, Blomqvist C, Knuutila S . 1997 Cancer Genet. Cytogenet. 99: 14–18

  • Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S . 1995 Cancer Res. 55: 1334–1338

  • Tarkkanen M, Elomaa I, Blomqvist C, Kivioja AH, Kellokumpu-Lehtinen P, Bohling T, Valle J, Knuutila S . 1999 Int. J. Cancer 84: 114–121

  • Weber RG, Pietsch T, von Schweinitz D, Lichter P . 2000a Am. J. Pathol. 157: 571–578

  • Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, Buschges R, Weigel R, Deckert-Schluter M, Schmiedek P, Reifenberger G, Lichter P . 2000b Brain Pathol. 10: 73–84

  • Yeh WC, Li TK, Bierer BE, McKnight SL . 1995 Proc. Natl. Acad. Sci. USA 92: 11081–11085

Download references

Acknowledgements

We are grateful to J Høie and P Helgerud for supplying clinical samples and AE Stenwig and B Bjerkehagen for the histological classification of tumours. Additional recognition to The Sanger Center for providing PACs identified by sequence homology during this study, and to Phil Rye and TJ Meza for critical reading of the manuscript. This work was supported by The Norwegian Research Council, the Norwegian Cancer Society, The Nordic Cancer Union, the European Union (through the Biomedicine and Health grant BMH4-CT96-0319), the Cancer Research Campaign, UK (SP 2475/0101) (Nizetic, South), Leiras Research Foundation (Knuutila, Tarkkanen) and Associazione Italiana per la Ricerca sul Cancro (AIRC) and of the Istituti Ortopedici Rizzoli (Ricerca Corrente and Ricerca Finalizzata) (Serra). The Celera Human Genome Sequence was kindly made available by Celera (www.celera.com) (Venter et al. (2001) Science, 291, 1304–1351).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ola Myklebost.

Additional information

COAS1, BG154169; COAS2, GI:4826471; COAS3, AF345651; KIAA1245, AB033071; Hypothetical gene spanning COAS1, AL117237.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meza-Zepeda, L., Forus, A., Lygren, B. et al. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene 21, 2261–2269 (2002). https://doi.org/10.1038/sj.onc.1205339

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205339

Keywords

This article is cited by

Search

Quick links